{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T15:32:53Z","timestamp":1793201573092,"version":"4.5.0"},"reference-count":27,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2015,4,28]],"date-time":"2015-04-28T00:00:00Z","timestamp":1430179200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Mult Scler"],"published-print":{"date-parts":[[2016,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Mobility impairment is a common disability in MS and negatively impacts patients\u2019 lives.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>Evaluate the effect of prolonged-release (PR) fampridine (extended-release dalfampridine in the United States) on self-assessed walking disability, dynamic\/static balance and safety in patients with MS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>MOBILE was a randomised, double-blind, exploratory, placebo-controlled trial. Patients with progressive\/relapsing-remitting MS and Expanded Disability Status Scale score of 4.0\u20137.0 were treated with PR-fampridine or placebo twice daily for 24 weeks. Efficacy endpoints included change from baseline in the 12-item MS Walking Scale (MSWS-12), Timed Up and Go (TUG) test and Berg Balance Scale (BBS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>132 patients were randomised at 24 sites in six countries. PR-fampridine therapy resulted in greater median improvements from baseline in MSWS-12 score, TUG speed and BBS total score versus placebo over 24 weeks. A higher proportion of patients receiving PR-fampridine versus placebo experienced significant improvements at MSWS-12 improvement thresholds \u2a7e7 ( p = 0.0275), \u2a7e8 ( p = 0.0153) and \u2a7e9 points ( p = 0.0088) and TUG speed thresholds \u2a7e10% ( p = 0.0021) and \u2a7e15% ( p = 0.0262). PR-fampridine was well tolerated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>PR-fampridine therapy resulted in early and sustained improvements in broad measures of walking and balance over six months.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1352458515581436","type":"journal-article","created":{"date-parts":[[2015,4,28]],"date-time":"2015-04-28T21:34:43Z","timestamp":1430256883000},"page":"212-221","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":61,"title":["Prolonged-release fampridine and walking and balance in MS: randomised controlled MOBILE trial"],"prefix":"10.1177","volume":"22","author":[{"given":"Raymond","family":"Hupperts","sequence":"first","affiliation":[{"name":"Orbis Medical Center, Sittard-Geleen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Lycke","sequence":"additional","affiliation":[{"name":"Institute of Neuroscience and Physiology, The Sahlgrenska Academy, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Short","sequence":"additional","affiliation":[{"name":"Queen Elizabeth II Health Sciences Centre, Halifax, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Gasperini","sequence":"additional","affiliation":[{"name":"Hospital San Camillo Forlanini, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manjit","family":"McNeill","sequence":"additional","affiliation":[{"name":"Biogen, Maidenhead, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Medori","sequence":"additional","affiliation":[{"name":"Biogen, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agata","family":"Tofil-Kaluza","sequence":"additional","affiliation":[{"name":"Biogen, Maidenhead, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Hovenden","sequence":"additional","affiliation":[{"name":"Excel Scientific Solutions, Southport, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lahar R","family":"Mehta","sequence":"additional","affiliation":[{"name":"Biogen, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Elkins","sequence":"additional","affiliation":[{"name":"Biogen, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2015,4,28]]},"reference":[{"key":"bibr1-1352458515581436","doi-asserted-by":"publisher","DOI":"10.1682\/JRRD.2009.07.0096"},{"key":"bibr2-1352458515581436","doi-asserted-by":"publisher","DOI":"10.17925\/ENR.2011.06.02.115"},{"key":"bibr3-1352458515581436","doi-asserted-by":"publisher","DOI":"10.1177\/1352458506070658"},{"key":"bibr4-1352458515581436","doi-asserted-by":"publisher","DOI":"10.1177\/1352458508088916"},{"key":"bibr5-1352458515581436","doi-asserted-by":"publisher","DOI":"10.1185\/03007990903433528"},{"key":"bibr6-1352458515581436","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22240"},{"key":"bibr7-1352458515581436","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60442-6"},{"key":"bibr8-1352458515581436","doi-asserted-by":"publisher","DOI":"10.1177\/135245859900500409"},{"key":"bibr9-1352458515581436","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.60.1.31"},{"key":"bibr10-1352458515581436","first-page":"875648","volume":"2013","author":"Nogueira LA","year":"2013","journal-title":"Mult Scler Int"},{"key":"bibr11-1352458515581436","doi-asserted-by":"publisher","DOI":"10.1191\/1352458506ms1293oa"},{"key":"bibr12-1352458515581436","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2013.02.021"},{"key":"bibr13-1352458515581436","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-010-0128-0"},{"key":"bibr14-1352458515581436","doi-asserted-by":"publisher","DOI":"10.1016\/j.apmr.2007.07.032"},{"key":"bibr15-1352458515581436","first-page":"802307","volume":"2014","author":"Prosperini L","year":"2014","journal-title":"Mult Scler Int"},{"key":"bibr16-1352458515581436","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.1991.tb01616.x"},{"key":"bibr17-1352458515581436","doi-asserted-by":"publisher","DOI":"10.1080\/09638280500404289"},{"key":"bibr18-1352458515581436","doi-asserted-by":"publisher","DOI":"10.1080\/09638280701191859"},{"key":"bibr19-1352458515581436","doi-asserted-by":"publisher","DOI":"10.1002\/ana.1032"},{"key":"bibr20-1352458515581436","doi-asserted-by":"publisher","DOI":"10.1191\/1352458505ms1135oa"},{"key":"bibr21-1352458515581436","volume-title":"ECDEU assessment manual for psychopharmacology","author":"Guy W.","year":"1976"},{"key":"bibr22-1352458515581436","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/124.5.962"},{"key":"bibr23-1352458515581436","unstructured":"EuroQoL Group. EQ-5D: A standardized instrument for use as a measurement of health outcome. Available at: http:\/\/www.euroqol.org\/, 2014 (accessed 24 October 2014)."},{"key":"bibr24-1352458515581436","first-page":"P509","volume":"16","author":"Hobart J","year":"2010","journal-title":"Mult Scler"},{"key":"bibr25-1352458515581436","first-page":"P665","volume":"19","author":"Macdonell R","year":"2013","journal-title":"Mult Scler"},{"key":"bibr26-1352458515581436","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S41596"},{"key":"bibr27-1352458515581436","unstructured":"Efficacy and Safety Study of Prolonged-Release Fampridine in Subjects With Multiple Sclerosis (ENHANCE). Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02219932, 2014 (accessed 24 October 2014)."}],"container-title":["Multiple Sclerosis Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1352458515581436","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1352458515581436","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1352458515581436","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T03:44:03Z","timestamp":1777693443000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1352458515581436"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,28]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["10.1177\/1352458515581436"],"URL":"https:\/\/doi.org\/10.1177\/1352458515581436","relation":{},"ISSN":["1352-4585","1477-0970"],"issn-type":[{"value":"1352-4585","type":"print"},{"value":"1477-0970","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,28]]}}}